Adult acute myeloid leukaemia: Update on treatment

Medical Journal of Australia

Volumn 170, Issue 1, 1999, Pages 39-43

  Bishop, James F ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMSACRINE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CEPHALOSPORIN; CYTARABINE; CYTOKINE; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; IDARUBICIN; MITOXANTRONE;

AGE; ALLOGENIC BONE MARROW TRANSPLANTATION; ANEMIA; BLOOD CELL COUNT; BONE MARROW DEPRESSION; CANCER MORTALITY; CANCER REGRESSION; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; DRUG MEGADOSE; DRUG TOLERANCE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; INFECTION COMPLICATION; LEUKOPENIA; MORBIDITY; MYELOID LEUKEMIA; NEUTROPENIA; REVIEW; SIBLING; THROMBOCYTOPENIA;

EID: 0033521657     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.1999.tb126866.x     Document Type: Review

References (36)

1. Jelfs P, Giles G, Shugg D, et al, editors. Cancer in Australia. Canberra: Australian Institute of Health and Welfare, 1995: 187-220.
2. Wiernik PH, Banks PC, Case DC, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adults with acute myeloid leukemia. Blood 1992; 79: 313-319.
3. Bishop JF, Lowenthal RM, Joshua D, et al. Etoposide in acute non-lymphocytic leukemia. Blood 1990; 75: 1-6.
4. Bishop JF. The treatment of adult acute myeloid leukemia. Semin Oncol 1997; 24: 57-69.
5. Louie AC, Issell BF. Amsacrine (AWSA) - a clinical review. J Clin Oncol 1985; 3: 562.
6. Estey EH, Keating MJ, McCredie KB, et al. Phase II trial of mitoxantrone in refractory acute leukemia. Cancer Treat Rep 1983; 67: 389-390.
7. Plunkett W, Iacoboni S, Keating MJ. Cellular pharmacology and optimal therapeutic concentrations of 1-β-D-arabinofuranosylcytosine 5 triphosohate in leukemic blasts during treatment of refractory leukemia with high dose 1-β-D-arabinofuranosylcytosine. Scand J Haematol 1986; 44: 51-59.
8. Rustum YM, Preisler HD. Correlation between leukemic cell retention of 1-β-D-arabinofuranosyteytosine 5 triphosphate and response to therapy. Cancer Res 1979; 39: 42-49.
9. Bishop JF, Matthews JP, Young GA, et al. A randomised study of high dose cytarabine in induction in acute myeloid leukemia. Blood 1996; 87: 1710-1717.
10. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive post-remission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994; 331: 896-903.
11. Chanock SJ, Pizzo PA. Infectious complications of patients undergoing therapy for acute leukemia. Semin Oncol 1997; 24: 132-140.
12. Bishop JF, Matthews JP, Young G, et al. Factors predicting death in induction therapy of acute myeloid leukemia. Proc Am Soc Clin Oncol 1993; 12: 210.
13. Bruckner T, Hiddeman W, Worman B, et al. Hematopoietic growth factors in acute myeloid eukemia: supportive and priming effects. Semin Oncol 1997; 24: 124-132.
14. Heil G, Sanz MA, Lechner K, et al. Results of a randomised, double-blind placebo controlled phase III study of filgrastim in remission induction and early consolidation therapy for adults with de novo acute myeloid leukemia [abstract]. Blood 1995; 86: 267-278.
15. Bishop JF, McGrath K, Wolf MM, et al. Clinical factors influencing the efficacy of pooled platelet transfusions. Blood 1988; 71: 383-387.
16. Mayer RJ, Weinstein HJ, Coral FS, et al. The role of intensive post induction chemotherapy in the management of patients with acute myelogenous leukemia Cancer Treat Rep 1982; 66: 1455-1462.
17. Cassileth PA, Lynch E, Hines JD, et al. Varying intensity of post-remission therapy in acute myeloid leukemia. Blood 1992; 79: 1924-1930.
18. Applebaum FR. Allogeneic hematopoietic stem cell transplantation for acute leukemia. Semin Oncol 1997; 24: 114-123.
19. Clift RA, Buckner CD, Thomas ED, et al. The treatment of acute non-lymphocytic leukemia by allogeneic marrow transplantation. Bone Marrow Transplant 1987; 2: 243-258.
20. Kernan NA, Bartsch G, Ash RC, et al. Retrospective analysis of 462 unrelated marrow transplants facilitated by the National Marrow Donor Program (NMDP) for treatment of congenital disorders of the lymphohematopoietic system and congenital metabolic disorders. N Engl J Med 1993; 328: 593-602.
21. Bessinger WI, Weaver CH, Applebaum FR et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995; 85: 1659-1665.
22. Bishop JF. Intensified therapy for acute myeloid leukemia [editorial]. N Engl J Med 1994; 331: 941-942.
23. Rubin EH, Anderson JW, Berg DT, et al. Risk factors for high dose cytarabine neurotoxicity: an analysis of a Cancer and Leukemia Group B trial in patients with acute myeloid leukemia. J Clin Oncol 1992; 10: 948-953.
24. Büchner T, Hiddeman W, Worman B, et al. Haematopoietic growth factors in acute myeloid leukaemia: supportive and priming effects. Semin Oncol 1997; 24: 124-131.
25. Keating MJ, Smith TL, Gehan EA, et al. A prognostic factor analysis for use in the development of predictive models for response in adult acute leukemia. Cancer 1982; 50: 457-465.
26. Swansbury GJ, Lawler SD, Alimena G, et al. Long term survival in acute myelogenous leukemia: a second follow up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer Genet Cytogenet 1994; 73: 1-7.
27. Woop P, Burgess R, MacGregor A, et al. P-glycoprotein expression on acute myeloid leukemia blast cells at diagnosis predicts response to chemotherapy and survival. Br J Haematol 1994; 87: 509-514.
28. Hart SM, Ganeshagurn K, Hoffbrand AV, et al. Expression of multi-drug resistance-associated protein (MRP) in acute leukemia Leukemia 1994; 8: 2163-2168.
29. Maung ZT, MacLean FR, Reid MM, et al. The relationship between bcl-2 expression and response to chemotherapy in acute leukemia. Br J Haematol 1994; 88: 105-109.
30. Leith CP, Chen IM, Kopckey KJ, et al. Correlation of multi-drug resistance (MDRI) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry. Blood 1995; 86: 2329-2342.
31. Huang ME, Ye YC, Chai JR, et al. Use of all-trans-retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567-581
32. Warnell RM, Frankel SR, Miller WH, et al. Differentiation therapy of acute promyelocytic leukemia with tretoin (all-trans-retinoic acid). N Engl J Med 1991; 324: 1385-1394.
33. Wiley JS, Firkin FC. Reductions of pulmonary toxicity by prednisolone prophylaxis during all-trans retinoic acid treatment of acute promyelocytic leukaemia. Australian Leukemia Study Group. Leukemia 1995; 9: 774-778.
34. Head DR, Kopecky KJ, Willman C, et al. Treatment outcome with chemotherapy in acute promyelocytic leukemia the South West Oncology Group (SWOG) experience Leukemia 1994; 8 (Suppl 2): S38-S41.
35. Larson RA, Kondo K, Vardiman JW, et al. Evidence for a 15:17 translocation in every patient with acute promyelocytic leukemia. Am J Med 1984; 76: 827-841.
36. Miller WH, Kakizuka A, Frankel SR, et al. Reverse transcriptase polymerase chain reaction for the rearranged retinoic acid receptor a clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proc Natl Acad Sci USA 1992; 89: 2694-2698.